glp 1 heart failure Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit GLP-1 Agonists in Cardiovascular Diseases:
Description
Tirzepatide was approved by the FDA for the treatment of diabetes in May 2022 and a few months later in the European Union, Canada and Australia
Data for GLP-1 analogs and ulcerative colitis There is reason to think GLP-1 analogs could be beneficial for inflammatory bowel disease (IBD) patients
Potcovaru CG, Filip PV, Neagu OM, Diaconu LS, Salmen T, Cintez D, et al
Li C, Zhou L, Sun H, Yang MM
doi: 10.1016/j.neuropharm.2014.04.007 100 CuiSSFengXBZhangBHXiaZYZhanLY
